Barinthus Biotherapeutics plc

BRNS

NASDAQ

Healthcare

Biotechnology

Didcot, GB105 employeesbarinthusbio.com

$0.57

+0.03(5.72%)

Mkt Cap $23M

$0.54

$1.97

52-Week Range

At a Glance

AI-generated

Barinthus Biotherapeutics plc reported a net loss attributable to shareholders of $66.4 million for FY 2025, compared to a net loss of $61.2 million in FY 2024.

Revenue breakdown: License (100%).

$23M

Market Cap

—

Revenue

-$67M

Net Income

Employees105

Fundamentals

How The Business Makes Money

Revenue by Segment

License100%($15M)

Activity

What Changed Recently

Management Change

Mar 30, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** As previo

Delisting

Jan 5, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 30, 2025, Barinthus Biotherapeutics plc (the

Financial Results

Mar 12, 2026

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan

Material Agreement

Feb 22, 2026

Entry into a Material Definitive Agreement. Amendment to the Merger Agreement As previously disclosed, on September 29, 2025, Barinthus Biotherapeutics plc, a p

Company Profile

CIK0001828185

ISINUS91864C1071

Phone44 1865 818 808

AddressZeus Building, Didcot, OX11 0DF, GB

SEC EDGAR